Revised EQA timetable published
Our EQA scheme timetable was impacted by the COVID-19 pandemic. Please click the link below for the revised timetable (published 01.07.2020).
EMQN collaborates with QCMD to provide a pilot EQA scheme for coronaviruses (SARS-CoV-2)
Please visit the READ MORE link below to learn more about this initiative.
EMQN and GenQA collaborate to launch pilot EQA for advanced (metastatic) Prostate Cancer
Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.
EMQN and GenQA collaborate to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer
Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.
We are a not-for-profit organisation promoting quality in genetic testing by establishing, harmonising and disseminating best practice.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
The latest news and press releases
Our EQA scheme timetable has been impacted by the COVID-19 pandemic. Please see https://t.co/eCXdoqcTEQ for a downl… https://t.co/1FtexNtzko
Provisional results from 2020 Germline EQA schemes have been published today - click https://t.co/6YcxDi53Cz for more details.
EMQN Best Practice Guidelines for DMD Published - https://t.co/09D0e3vFRr
Want to learn more about the results of our 2019 BRCA ovarian cancer schemes? Join EMQN and GenQA on our live webin… https://t.co/32reRhYaXU
ISSAID/EMQN Best Practice Guidelines for SAIDs/HRF Published - https://t.co/OSOY7gkAwY